Novelion Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2018
March 14, 2019 at 05:12 pm EDT
Novelion Therapeutics Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2018. GAAP total net revenues for the fourth quarter of 2018 were $40.7 million compared to $38.9 million for the same period in 2017. GAAP net loss in the fourth quarter of 2018 was $19.4 million, an improvement of approximately 21.1% compared to GAAP net loss of $24.6 million during the same period in 2017. Income from operations was $1,031,000 compared to loss of $13,964,000 a year ago. Basic and diluted net loss per common share was $1.03 compared to $1.32 a year ago.
GAAP total net revenues for the year ended December 31, 2018 were $130.4 million compared to $138.4 million for 2017. GAAP net loss for the year ended December 31, 2018 was $108.3 million compared to GAAP net loss of $126.7 million for 2017. Loss from operations was $50,067,000 compared to loss of $86,798,000 a year ago. Basic and diluted net loss per common share was $5.76 compared to $6.81 a year ago.